

Originator: Steven Courtney

Tel: 247 4707

Report of the Head of Scrutiny and Member Development

Scrutiny Board (Health)

Date: 26 October 2010

Subject: Pharmaceutical Needs Assessment

| Electoral Wards Affected: | Specific Implications For: |
|--|----------------------------|
| | Equality and Diversity |
| | Community Cohesion |
| Ward Members consulted (referred to in report) | Narrowing the Gap |

1.0 **Purpose of this Report**

1.1 The purpose of the report is to present the Scrutiny Board (Health) with details of the current draft Pharmaceutical Needs Assessment (PNA) for Leeds – which is intended to inform the decision-making in relation to pharmaceutical services over the next three years. An outline of the proposed stakeholder consultation is also detailed.

2.0 Background

- 2.1 Current legislation places a duty on local NHS Trusts, Primary Care Trusts and Strategic Health Authorities to make arrangements to involve and consult patients and the public in the planning and development of local health services, and decisions about changes to the operation of those services.
- 2.2 The requirement to consult on service changes and/or developments, also includes a duty to consult the local Health Scrutiny Board where the NHS Body has under consideration any proposal for a major development and/or variation of the health service, relevant to the local authority's area.

3.0 Pharmaceutical Needs Assessment

- 3.1 The Department of Health has introduced legislation which requires all primary care trusts (PCTs) to have a Pharmaceutical Needs Assessment (PNA) in place by February 2011. The PNA is intended to inform the decision making in relation to pharmaceutical services within NHS Leeds over the next three years.
- 3.2 A draft PNA has been developed by NHS Leeds with support from the Leeds Local Pharmaceutical Committee and is now ready for consultation with stakeholders. A full

hard-copy consultation pack will be provided for all members of the Scrutiny Board prior to the meeting. In addition, details are available to view from the following web link: <u>http://www.leeds.nhs.uk/Have-your-say/Do-you-want-to/Have-your-say-on-public-consultations.htm</u>

Consultation

- 3.3 The consultation will run from 4 October 2010 to 31 December 2010 and NHS Leeds welcomes your views on the document during this time period. Any comments received as part of the consultation will be used to inform the development of the PNA. To support the consultation, there will also be a number of stakeholder events:
 - Wednesday 20th October 2010, 13:00 14:00 and 14:00 15:00 at Wetherby Health Centre
 - Monday 15th November, 11:00 12:00 and 12:00 13:00 at Beeston Hill Community Health Centre
 - Wednesday 27th October, 10:00 11:00 and 11:00 12:00 at Yeadon Health Centre
- 3.4 Further consultation events will be published on the NHS Leeds website, at <u>www.leeds.nhs.uk</u>
- 3.5 Appropriate representatives from NHS Leeds have been invited to attend the Scrutiny Board meeting to outline the Pharmaceutical Needs Assessment (PNA) and its associated implications; and to address any relevant matters identified by the Board.

Role of the Scrutiny Board

- 3.6 In considering the information presented in relation to the Pharmaceutical Needs Assessment and supporting consultation details, the role of the Board could be two-fold, namely:
 - (a) To seek assurance around the proposed consultation; and/or,
 - (b) Provide an agreed response as part of the consultation process.
- 3.7 The Board is asked to have regard to these roles when considering the details presented and discussed at the meeting.

4.0 Recommendation

4.1 Within the scope of the role of the Scrutiny Board (outlined in paragraph 3.6 above), members of Scrutiny Board are asked to consider the information presented and determine any specific matters the Board may wish to raise as part of the consultation process.

5.0 Background Papers

• None.